Loading organizations...
Hanne Capital is a healthcare-focused venture capital and private equity fund based in Greater China, investing in early-stage and growth-stage opportunities within the healthcare and biotechnology sectors. The firm specializes in novel drugs, medical devices, and innovative therapeutic platforms, such as peripheral and neurovascular interventional devices, immunotherapy, and antibody drug development. Operating with a typical "7+2" fund cycle, its portfolio features Zylox-Tonbridge Medical (HK:02190), which went public approximately three years post-investment, and HiFiBiO Therapeutics, which secured a $67 million Series C round in 2019. Hanne Capital has also co-invested alongside notable firms such as IDG Capital, Sequoia Capital China, and VI Ventures. Founded in 2017 by Edward Zhou, the firm targets companies with strong founding teams and intrinsic business value.
Key people at Hanne Capital.
Hanne Capital was founded in 2017 by Edward Zhou (Founder & Managing Partner).
Key people at Hanne Capital.
Hanne Capital has 1 tracked investment across 1 company. The latest tracked deal is $67.0M Series C in HiFiBiO in August 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 28, 2019 | HiFiBiO | $67.0M Series C | IDG Capital | Delian Capital, Hongshan Capital Group (Sequoia Capital China), Kite, Lyfe Capital, VI Ventures |
Hanne Capital was founded in 2017 by Edward Zhou (Founder & Managing Partner).
